109 related articles for article (PubMed ID: 2359989)
1. Absorption of oral mesalazine-containing preparations and the influence of famotidine on the absorption.
Wiltink EH; Mulder CJ; Stolk LM; Rietbroek R; Verbeek C; Tytgat GN
Scand J Gastroenterol; 1990 Jun; 25(6):579-84. PubMed ID: 2359989
[TBL] [Abstract][Full Text] [Related]
2. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.
Christensen LA; Fallingborg J; Abildgaard K; Jacobsen BA; Sanchez G; Hansen SH; Bondesen S; Hvidberg EF; Rasmussen SN
Aliment Pharmacol Ther; 1990 Oct; 4(5):523-33. PubMed ID: 2129640
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability of controlled release mesalazine (5-ASA) preparations.
Rasmussen SN
J Gastroenterol; 1995 Nov; 30 Suppl 8():112-4. PubMed ID: 8563869
[TBL] [Abstract][Full Text] [Related]
4. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.
Rijk MC; van Schaik A; van Tongeren JH
Scand J Gastroenterol; 1992 Oct; 27(10):863-8. PubMed ID: 1359629
[TBL] [Abstract][Full Text] [Related]
5. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
6. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Sandborn WJ; Hanauer SB
Aliment Pharmacol Ther; 2003 Jan; 17(1):29-42. PubMed ID: 12492730
[TBL] [Abstract][Full Text] [Related]
7. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.
De Vos M; Verdievel H; Schoonjans R; Praet M; Bogaert M; Barbier F
Gut; 1992 Oct; 33(10):1338-42. PubMed ID: 1446856
[TBL] [Abstract][Full Text] [Related]
8. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.
Abinusawa A; Tenjarla S
Adv Ther; 2015 May; 32(5):477-84. PubMed ID: 25951927
[TBL] [Abstract][Full Text] [Related]
9. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
Staerk Laursen L; Stokholm M; Bukhave K; Rask-Madsen J; Lauritsen K
Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
[TBL] [Abstract][Full Text] [Related]
10. Dissolution profiles of mesalazine formulations in vitro.
Stolk LM; Rietbroek R; Wiltink EH; Tukker JJ
Pharm Weekbl Sci; 1990 Oct; 12(5):200-4. PubMed ID: 2255590
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
Sandborn WJ; Hanauer SB; Buch A
Aliment Pharmacol Ther; 2004 May; 19(10):1089-98. PubMed ID: 15142198
[TBL] [Abstract][Full Text] [Related]
12. Steady state disposition of 5-aminosalicyclic acid following oral dosing.
Klotz U; Stracciari GL
Arzneimittelforschung; 1993 Dec; 43(12):1357-9. PubMed ID: 8141827
[TBL] [Abstract][Full Text] [Related]
13. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
Ewe K; Becker K; Ueberschaer B
Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
[TBL] [Abstract][Full Text] [Related]
14. Delivery and fate of oral mesalamine microgranules within the human small intestine.
Layer PH; Goebell H; Keller J; Dignass A; Klotz U
Gastroenterology; 1995 May; 108(5):1427-33. PubMed ID: 7729635
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation.
Christensen LA; Fallingborg J; Jacobsen BA; Abildgaard K; Rasmussen HH; Hansen SH; Rasmussen SN
Aliment Pharmacol Ther; 1994 Jun; 8(3):289-94. PubMed ID: 7918923
[TBL] [Abstract][Full Text] [Related]
16. Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosing.
Vree TB; Dammers E; Exler PS; Maes RA
J Pharm Pharmacol; 2000 Jun; 52(6):645-52. PubMed ID: 10875540
[TBL] [Abstract][Full Text] [Related]
17. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
Christensen LA; Jacobsen BA
Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
[TBL] [Abstract][Full Text] [Related]
18. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.
Riley SA; Tavares IA; Bennett A; Mani V
Br J Clin Pharmacol; 1988 Aug; 26(2):173-7. PubMed ID: 3207553
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine.
Corey AE; Rose GM; Conklin JD
J Int Med Res; 1990; 18(6):441-53. PubMed ID: 1981363
[TBL] [Abstract][Full Text] [Related]
20. Effect of increasing gastric pH with famotidine on the absorption and oral pharmacokinetics of the inotropic agent vesnarinone.
Koneru B; Cowart DT; Noorisa M; Kisicki J; Bramer SL
J Clin Pharmacol; 1998 May; 38(5):429-32. PubMed ID: 9602955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
